Search Result

Results for "

SARS-CoV

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SARS-CoV (451) 11β-HSD (3) 5-HT Receptor (1) AAK1 (2) Akt (1) Angiotensin-converting Enzyme (ACE) (6) Antibiotic (12) Apoptosis (20) Autophagy (25) Bacterial (13) Bcr-Abl (2) c-Kit (2) Calcium Channel (2) Casein Kinase (3) Cathepsin (15) CCR (1) CDK (1) Ceramidase (1) Cholinesterase (ChE) (2) COX (2) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (7) Dengue virus (2) Deubiquitinase (1) DNA Methyltransferase (1) DNA/RNA Synthesis (13) Dopamine Receptor (6) Drug Metabolite (6) Endogenous Metabolite (8) Eukaryotic Initiation Factor (eIF) (1) FAAH (1) Fatty Acid Synthase (FASN) (2) Ferroptosis (1) Filovirus (3) Flavivirus (2) Fluorescent Dye (1) Fungal (2) FXR (1) G-quadruplex (1) Glutathione Peroxidase (1) HBV (1) HCV (27) HCV Protease (17) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (5) Histone Methyltransferase (2) HIV (36) HIV Protease (21) HSP (1) HSV (3) Influenza Virus (11) Interleukin Related (1) Isotope-Labeled Compounds (25) Keap1-Nrf2 (2) Lipoxygenase (1) MDM-2/p53 (1) Mitophagy (1) MMP (4) nAChR (1) NF-κB (2) Nucleoside Antimetabolite/Analog (1) Opioid Receptor (2) Orthopoxvirus (1) P-glycoprotein (5) PAI-1 (1) Parasite (30) PDGFR (2) Phosphatase (2) PI3K (1) PKC (2) Potassium Channel (2) PROTACs (3) Ras (1) Reactive Oxygen Species (2) Reverse Transcriptase (2) ROS Kinase (2) RSV (2) Ser/Thr Protease (8) Sigma Receptor (3) Sirtuin (3) Sodium Channel (7) STING (9) Telomerase (1) Toll-like Receptor (TLR) (18) Topoisomerase (2) TRP Channel (1) VEGFR (1) Virus Protease (19)
By Research Areas:	Cancer (79) Cardiovascular Disease (9) Endocrinology (7) Infection (435) Inflammation/Immunology (48) Metabolic Disease (23) Neurological Disease (14)

By Targets:

SARS-CoV (451)

11β-HSD (3)

5-HT Receptor (1)

AAK1 (2)

Akt (1)

Angiotensin-converting Enzyme (ACE) (6)

Antibiotic (12)

Apoptosis (20)

Autophagy (25)

Bacterial (13)

Bcr-Abl (2)

c-Kit (2)

Calcium Channel (2)

Casein Kinase (3)

Cathepsin (15)

CCR (1)

CDK (1)

Ceramidase (1)

Cholinesterase (ChE) (2)

COX (2)

Cyclin G-associated Kinase (GAK) (1)

Cytochrome P450 (7)

Dengue virus (2)

Deubiquitinase (1)

DNA Methyltransferase (1)

DNA/RNA Synthesis (13)

Dopamine Receptor (6)

Drug Metabolite (6)

Endogenous Metabolite (8)

Eukaryotic Initiation Factor (eIF) (1)

FAAH (1)

Fatty Acid Synthase (FASN) (2)

Ferroptosis (1)

Filovirus (3)

Flavivirus (2)

Fluorescent Dye (1)

Fungal (2)

FXR (1)

G-quadruplex (1)

Glutathione Peroxidase (1)

HBV (1)

HCV (27)

HCV Protease (17)

HIF/HIF Prolyl-Hydroxylase (1)

Histamine Receptor (5)

Histone Methyltransferase (2)

HIV (36)

HIV Protease (21)

HSP (1)

HSV (3)

Influenza Virus (11)

Interleukin Related (1)

Isotope-Labeled Compounds (25)

Keap1-Nrf2 (2)

Lipoxygenase (1)

MDM-2/p53 (1)

Mitophagy (1)

MMP (4)

nAChR (1)

NF-κB (2)

Nucleoside Antimetabolite/Analog (1)

Opioid Receptor (2)

Orthopoxvirus (1)

P-glycoprotein (5)

PAI-1 (1)

Parasite (30)

PDGFR (2)

Phosphatase (2)

PI3K (1)

PKC (2)

Potassium Channel (2)

PROTACs (3)

Ras (1)

Reactive Oxygen Species (2)

Reverse Transcriptase (2)

ROS Kinase (2)

RSV (2)

Ser/Thr Protease (8)

Sigma Receptor (3)

Sirtuin (3)

Sodium Channel (7)

STING (9)

Telomerase (1)

Toll-like Receptor (TLR) (18)

Topoisomerase (2)

TRP Channel (1)

VEGFR (1)

Virus Protease (19)

By Research Areas:

Cancer (79)

Cardiovascular Disease (9)

Endocrinology (7)

Infection (435)

Inflammation/Immunology (48)

Metabolic Disease (23)

Neurological Disease (14)

494

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

185

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: SARS-CoV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136606

SARS-CoV MPro-IN-1	SARS-CoV	Infection
SARS-CoV MPro-IN-1 is a SARS-CoV-2 3CLpro covalent inhibitor, with an IC₅₀ of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC₅₀ of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research .

HY-N144101

SARS-CoV MPro-IN-2	SARS-CoV	Infection
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M ^pro with an IC₅₀ value of 72.07 nM. The main protease (M ^pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .

HY-147516

SARS-CoV-2-IN-21	SARS-CoV	Infection
SARS-CoV-2-IN-21 (compound 10), a penicillin sulfone benzyl C6 derivative, is a potent SARS-CoV-2 main protease inhibitor, with an IC₅₀ of 5.3 μM. SARS-CoV-2-IN-21 can be used for COVID-19 research .

HY-143467

SARS-CoV-IN-4

SARS-CoV Infection

SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC₅₀ of 0.6 μM (SARS-CoV nsp14) .

SARS-CoV-IN-4	SARS-CoV	Infection
SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC₅₀ of 0.6 μM (SARS-CoV nsp14) .

HY-150783

SARS-CoV-2-IN-24	SARS-CoV	Infection
SARS-CoV-2-IN-24 (compound 7) is a potent papain-like protease (PL ^pro) inhibitor. SARS-CoV-2-IN-24 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. SARS-CoV-2-IN-24 can be used for SARS-CoV-2 research .

HY-155119

SARS-CoV-2-IN-54	SARS-CoV	Infection
SARS-CoV-2-IN-54 (Compound 2) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-54 has antiviral activity. SARS-CoV-2-IN-54 inhibits SARS-CoV-2 in Vero E6 cells, with an IC₅₀ of 21.4 μM .

HY-155121

SARS-CoV-2-IN-56	SARS-CoV	Infection
SARS-CoV-2-IN-56 (Compound 63) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-56 has antiviral activity. SARS-CoV-2-IN-56 inhibits SARS-CoV-2 in Vero E6 cells, with an IC₅₀ of 0.7 μM .

HY-149954

SARS-CoV-2-IN-39	SARS-CoV	Infection
SARS-CoV-2-IN-39 (compound 21) is a *SARS-CoV-2* inhibitor with an EC₅₀ of 1 μM. SARS-CoV-2-IN-39 against SARS-CoV-2 by inhibiting of SKP2 protein and stabilizing BECN1 .

HY-156008

SARS-CoV-2-IN-58	SARS-CoV Virus Protease	Infection
SARS-CoV-2-IN-58 (Compound 21H) is an antiviral agent against *SARS-CoV-2* (EC₅₀: 18 μM). SARS-CoV-2-IN-58 inhibits SARS-CoV-2 M ^pro with an IC₅₀ of 0.35 μM .

HY-151988

SARS-CoV-2-IN-36	SARS-CoV	Infection
SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC₅₀ of 2.37 μM and a K_d of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells .

HY-155015

SARS-CoV-2-IN-45	SARS-CoV	Infection
SARS-CoV-2-IN-45 (Compound 8p) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC₅₀ of 0.5 μM, and has no evident cytotoxic effect .

HY-162154

SARS-CoV-2-IN-75	SARS-CoV	Infection
SARS-CoV-2-IN-75 (compound 13) is a *SARS-CoV-2* inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC₆₈ (half-log reduction in viral titer) of 3 μM .

HY-135860

SARS-CoV-2-IN-1	Virus Protease SARS-CoV	Infection
SARS-CoV-2-IN-1 is a potent Mpro inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC₅₀s of 0.67, 0.90 and 0.58 μM, respectively .

HY-162177

SARS-CoV-2-IN-78

SARS-CoV Infection

SARS-CoV-2-IN-78 (compound 3) is an inhibitor for nsp14 of SARS-Cov-2. SARS-CoV-2-IN-78 reveals antiviral activity as N7 methyltrabsferase .

SARS-CoV-2-IN-78	SARS-CoV	Infection
SARS-CoV-2-IN-78 (compound 3) is an inhibitor for nsp14 of *SARS-Cov-2. SARS-CoV*-2-IN-78 reveals antiviral activity as N7 methyltrabsferase .

HY-149304

SARS-CoV-2-IN-40	SARS-CoV	Infection
SARS-CoV-2-IN-40 (Compound 19) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC₅₀s of 100 nM and 160 nM respectively .

HY-146379

SARS-CoV-2-IN-19	SARS-CoV	Infection
SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .

HY-143417

SARS-CoV-2-IN-16	SARS-CoV	Infection
SARS-CoV-2-IN-16 (Compound 12) is a potent *SARS-CoV-2* nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-16 exhibits potent anti-viral activity with the EC₅₀ of 3.69 μM. SARS-CoV-2-IN-16 binds to NPro with the low K_D value of 7.82 μM, suggesting that SARS-CoV-2-IN-16 is a potent NPro ligand .

HY-143418

SARS-CoV-2-IN-17	SARS-CoV	Infection
SARS-CoV-2-IN-17 (Compound 16) is a potent *SARS-CoV-2* nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-17 exhibits potent anti-viral activity with the EC₅₀ of 2.18 μM. SARS-CoV-2-IN-17 binds to NPro with the low K_D value of 7.82 μM, suggesting that SARS-CoV-2-IN-17 is a potent NPro ligand .

HY-157145

SARS-CoV-2-IN-69	SARS-CoV	Infection
SARS-CoV-2-IN-69 (Compound 7E) is a non-covalent *SARS-CoV-2* inhibitor with an EC₅₀ value of 7.4 μM. SARS-CoV-2-IN-69 is a potent inhibitor of SARS-CoV-2 main protease (M ^pro) and a non-covalent inhibitor of papain (PL ^pro) .

HY-163067

SARS-CoV-2-IN-71	SARS-CoV	Infection
SARS-CoV-2-IN-71 (compound 8h) is a potent inhibitor of *SARS-CoV-2. SARS-CoV-2-IN-71 inhibits coronavirus replication at multiple stages. SARS-CoV-2-IN-71 displays anti-coronaviral effect by simultaneously acting on 3CL ^pro* and TMPRSS2 .

HY-146381

SARS-CoV-2-IN-20	SARS-CoV	Infection
SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases .

HY-154975

SARS-CoV-2-IN-49

SARS-CoV Others

SARS-CoV-2-IN-49 is an irreversible covalent inhibitor of SARS-CoV-2 main protease .

SARS-CoV-2-IN-49	SARS-CoV	Others
SARS-CoV-2-IN-49 is an irreversible covalent inhibitor of *SARS-CoV-2* main protease .

HY-145276

SARS-CoV-2-IN-10	SARS-CoV	Infection
SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-145277

SARS-CoV-2-IN-11	SARS-CoV	Infection
SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-149315

SARS-CoV-2-IN-48

SARS-CoV Infection

SARS-CoV-2-IN-48 (compound 19) is a SARS-CoV-2 inhibitor with an IC₅₀ of 2.7 μM for Omicron BA.1. SARS-CoV-2-IN-48 shows antiviral activities .

SARS-CoV-2-IN-48	SARS-CoV	Infection
SARS-CoV-2-IN-48 (compound 19) is a *SARS-CoV-2* inhibitor with an IC₅₀ of 2.7 μM for Omicron BA.1. SARS-CoV-2-IN-48 shows antiviral activities .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-148387

SARS-CoV-2-IN-35	SARS-CoV	Infection
SARS-CoV-2-IN-35 is a potent and orally active SARS-CoV-2 M ^pro inhibitor with a K_i value of 12.1 nM. SARS-CoV-2-IN-35 can be used in research of COVID-19 .

HY-149868

SARS-CoV-2-IN-42	SARS-CoV	Infection
SARS-CoV-2-IN-42 (Compound 8q) is a potent inhibitor of *SARS-CoV-2* replication (EC₅₀: 0.4 μM). SARS-CoV-2-IN-42 has no obvious damage to the host cell .

HY-157144

SARS-CoV-2-IN-68	SARS-CoV	Infection
SARS-CoV-2-IN-68 (compound 6C) is a covalent SARS-CoV-2 PLpro/Mpro inhibitor with potent antiviral activities. SARS-CoV-2-IN-68 binds to Zn-finger domain of PLpro .

HY-151267

SARS-CoV-2-IN-25	SARS-CoV	Infection
SARS-CoV-2-IN-25 (Compound CP026) is a potent *SARS-CoV-2* spike pseudoparticle transduction inhibitor with an IC₅₀ of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes .

HY-154976

SARS-CoV-2-IN-50	SARS-CoV	Infection
SARS-CoV-2-IN-50 (Compound X77C) is a *SARS-CoV-2* main protease (M ^Pro) inhibitor.. SARS-CoV-2-IN-50 has a high affinity to the catalytic site of M ^Pro .

HY-162151

SARS-CoV-2-IN-74	SARS-CoV	Infection
SARS-CoV-2-IN-74 (compound 30) is a epoxide inhibitor, which inhibits cellular SARS-CoV-2 replication with an EC₆₈ of 5 μM. SARS-CoV-2-IN-74 can be used for the research of coronavirus .

HY-139732

SARS-CoV-2-IN-8

SARS-CoV Infection

SARS-CoV-2-IN-8 is a SARS-CoV-2 main protease inhibitor with an IC₅₀ value of 0.75 μM.

SARS-CoV-2-IN-8	SARS-CoV	Infection
SARS-CoV-2-IN-8 is a *SARS-CoV-2* main protease inhibitor with an IC₅₀ value of 0.75 μM.

HY-157022

SARS-CoV-2-IN-67	SARS-CoV	Infection
SARS-CoV-2-IN-67 (Compound 16), a vitamin K derivatives, has anti-SARS-CoV-2 activity (EC₅₀: 64.8 μM in VeroE6/TMPRSS2 cells). SARS-CoV-2-IN-67 inhibits SARS-CoV-2 RdRp activity .

HY-155308

SARS-CoV-2-IN-61

SARS-CoV Infection

SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC₅₀ of 16 µM. SARS-CoV-2-IN-61 has antiviral activities .
HY-139866

SARS-CoV-2-IN-9

SARS-CoV Infection

SARS-CoV-2-IN-9 is an inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease.
HY-146157

SARS-CoV-2-IN-22

SARS-CoV Infection

SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC₅₀ value of 16.96 µM .
HY-149649

SARS-CoV-2-IN-64

SARS-CoV Infection

SARS-CoV-2-IN-64 (compound 9), a chenodeoxycholic acid derivative, is a potent inhibitor of spike glycoprotein of SARS-CoV-2 .
HY-162111

SARS-CoV-2-IN-73

SARS-CoV Infection

SARS-CoV-2-IN-73 (compound 4) is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) blocker .

SARS-CoV-2-IN-61	SARS-CoV	Infection
SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC₅₀ of 16 µM. SARS-CoV-2-IN-61 has antiviral activities .

SARS-CoV-2-IN-9	SARS-CoV	Infection
SARS-CoV-2-IN-9 is an inhibitor binding to subsites S1 and S2 in *SARS-CoV-2* main protease.

SARS-CoV-2-IN-22	SARS-CoV	Infection
SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC₅₀ value of 16.96 µM .

SARS-CoV-2-IN-64	SARS-CoV	Infection
SARS-CoV-2-IN-64 (compound 9), a chenodeoxycholic acid derivative, is a potent inhibitor of spike glycoprotein of SARS-CoV-2 .

SARS-CoV-2-IN-73	SARS-CoV	Infection
SARS-CoV-2-IN-73 (compound 4) is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) blocker .

HY-151900

SARS-CoV-2 Mpro-IN-4	SARS-CoV Virus Protease	Infection
SARS-CoV-2 Mpro-IN-4 is a dual Inhibitor of Main Protease (M ^Pro) and Cathepsin L (CatL), with IC₅₀s of 900 nM and 60 nM respectively. SARS-CoV-2 Mpro-IN-4 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-4 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC₅₀ value of 8.2 nM .

HY-151901

SARS-CoV-2 Mpro-IN-5	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-5 is a dual Inhibitor of Main Protease (M ^Pro) and Cathepsin L (CatL), with IC₅₀s of 1800 nM and 145 nM respectively. SARS-CoV-2 Mpro-IN-5 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-5 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC₅₀ value of 14.7 nM .

HY-161261

SARS-CoV-2-IN-81	AAK1 SARS-CoV	Infection
SARS-CoV-2-IN-81 (compound 12e) is a potent AAK1 inhibitor with an IC₅₀ value of 9.38 nM. SARS-CoV-2-IN-81 shows anti-viral property against *SARS-CoV-2. SARS-CoV-2-IN-81 attenuates AAK1-induced phosphorylation of AP2M1 threonine 156 and disrupts the direct interaction between AP2M1 and ACE2, ultimately inhibiting SARS-CoV*-2 infection .

HY-149368

SARS-CoV-2-IN-51	SARS-CoV	Infection
SARS-CoV-2-IN-51 (S-10) is a potent lead compound of Omicron fusion inhibitor. SARS-CoV-2-IN-51 inhibits Omicron and other variants with EC₅₀s of 0.82-5.45 μM. SARS-CoV-2-IN-51 inhibits SARS-CoV-2 virus entry, by the direct interaction with S in the prefusion state .

HY-157848

SARS-CoV-2-IN-82

SARS-CoV Infection

SARS-CoV-2-IN-82 (compound A) is a Programmed-1 ribosomal frameshift (-1 PRF) inhibitor of SARS-CoV-2 .

SARS-CoV-2-IN-82	SARS-CoV	Infection
SARS-CoV-2-IN-82 (compound A) is a Programmed-1 ribosomal frameshift (-1 PRF) inhibitor of SARS-CoV-2 .

HY-144771

SARS-CoV-2-IN-14	SARS-CoV	Infection
SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of *SARS-CoV-2* with an IC₅₀ of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-144772

SARS-CoV-2-IN-15	SARS-CoV	Infection
SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of *SARS-CoV-2* with an IC₅₀ of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-144770

SARS-CoV-2-IN-13	SARS-CoV	Infection
SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of *SARS-CoV-2* with an IC₅₀ of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-161238

SARS-CoV-2-IN-79	SARS-CoV	Infection
SARS-CoV-2-IN-79 (Compound 5) is a *SARS-CoV-2* inhibitor, with IC₅₀ and CC₅₀ values of 55 μg/mL and 311.6 μg/mL. SARS-CoV-2-IN-79 has the highest antiviral activity against (hCoV-19/Egypt/NRC-03/2020). SARS-CoV-2-IN-79 can be used for the research of COVID-19 .

HY-155014

SARS-CoV-2-IN-44	SARS-CoV	Infection
SARS-CoV-2-IN-44, a inhibitor of *SARS-CoV-2, inhibits viral replication, with an EC₅₀* of 0.6μM. SARS-CoV-2-IN-44 has no evident cytotoxic effect in Calu-3 cells and can be used for antiviral research .

HY-132886

SARS-CoV-2-IN-6

SARS-CoV Infection

SARS-CoV-2-IN-6 is a SARS-CoV-2 3CLpro inhibitor that shows the most potent enzyme inhibitory IC₅₀ value of 73 nM.

Cat. No.	Product Name

HY-L002

Anti-Infection Compound Library

2882 compounds

An infection occurs when another organism enters a person’s body and causes disease. The organisms that cause infections are very diverse and can include things like viruses, bacteria, fungi, and parasites. The immune system is an effective barrier against infectious agents.

MCE provides a unique collection of 2882 anti-infective compounds with anti-bacterial, anti-viral, anti-fungal and anti-parasite activities that can be used for drug screening and other research in anti-microbial area.

HY-L113

Antiviral Traditional Chinese Medicine Active Compound Library

171 compounds

Increasing research have shown that Traditional Chinese Medicine (TCM) possess antiviral activities against various viral strains, such as herpes simplex virus, influenza virus, hepatitis B and C viruses, and SARS-CoV. To date, dozens of Chinese herbs and hundreds of natural TCM ingredients have been reported to exhibit good antiviral activities. Active components from TCM are one of the important sources for antiviral drugs discovery.

MCE designs a unique collection of 171 active compounds of antiviral Chinese Herbal Medicines. MCE Antiviral Traditional Chinese Medicine Active Compound Library is a useful tool for discovery antiviral drugs from TCM.

HY-L027

Antiviral Compound Library

1270 compounds

Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs.

MCE designs a unique collection of 1270 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P4388

Z-Arg-Leu-Arg-Gly-Gly-AMC

SARS-CoV Infection

Z-Arg-Leu-Arg-Gly-Gly-AMC is a peptide substrate of SARS-CoV PL ^pro .

HY-P3258

SP-10	Cholinesterase (ChE)	Infection
SP-10 is a small peptide derived from S protein with an IC₅₀ value of 1.88 nM for blocks the interaction between S protein and ACE2. SP-10 can be used for SARS-CoV research .

HY-P5398

HR2-18

Peptides Others

HR2-18 is a biological active peptide. (inhibition of SARS-CoV penetration into cells.)
HY-P5416

GGASCCLYCRCH

Peptides Others

GGASCCLYCRCH is a biological active peptide. (can inhibit the 2-O-methyltransferase activity of the SARS-CoV complex nsp16/10)

HY-P2296

Abz-FRLKGGAPIKGV-EDDNP TFA	Fluorescent Dye	Others
Abz-FRLKGGAPIKGV-EDDNP TFA is a fluorogenic substrate used to measure the enzymatic activities of protease forms, such as papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV). Abz-FRLKGGAPIKGV-EDDNP TFA has the potential for study 2019-nCoV (COVID-19) infection .

HY-18234

Leupeptin	Ser/Thr Protease Virus Protease Cathepsin	Infection Inflammation/Immunology
Leupeptin is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin potently inhibits serine, cysteine and threonine proteases. Leupeptin inhibits M ^pro (the main protease of *SARS-CoV-2*) and also has anti-inflammatory activity .

HY-P5827

SBP1 peptide	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SBP1 peptide is a chemically synthesized 23-mer peptide fragment of the ACE2 PD α1 helix. SBP1 peptide associates with micromolar affinity to insect-derived *SARS-CoV-2*-RBD protein .

HY-P0012A

Aviptadil acetate 1 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P4307

Antioxidant agent-9	SARS-CoV	Infection
Antioxidant agent-9 is a peptide with the sequence Asp-Trp. Antioxidant agent-9 shows antioxidant activity. Antioxidant agent-9 also is potential as *SARS-CoV-2* antiviral, with an affinity strength equal to Chloroquine (HY-17589A) and Favipiravir (HY-14768) .

HY-P0012

Aviptadil 1 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-16050

Plitidepsin 2 Publications Verification Aplidine; PM90001	DNA/RNA Synthesis SARS-CoV	Infection Cancer
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against *SARS-CoV-2* with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-P3626

Astodrimer SPL7013 free base	Bacterial HCV SARS-CoV	Infection
Astodrimer (SPL7013 free base) is a large (3-4 nm, ~ 16.5 kDa), negatively charged, highly-branched dendrimer, is a potent virucidal agent. Astodrimer shows antiviral and virucidal activity against a broad spectrum of viruses, including SARS-CoV-2, HIV-1, HSV-1, HSV-2, HPV. Astodrimer also has antibacterial properties .

Cat. No.	Product Name	Target	Research Area

HY-P9807

*Anti-SARS-CoV-2 Spike mAb (CR3022)* SARS-CR3022; SARS-CoV-2 Antibody-CR3022	SARS-CoV	Infection Inflammation/Immunology
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .

HY-P9801

Anti-Spike-RBD mAb 1 Publications Verification SARS-CoV-2 (2019-nCoV) Spike RBD Antibody	SARS-CoV	Infection
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .

HY-P99344

Bamlanivimab Anti-Human SARS-CoV-2	SARS-CoV	Infection
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .

HY-P99423

Adintrevimab 1 Publications Verification ADG 20	SARS-CoV	Infection
Adintrevimab (ADG 20) is a human IgG1 monoclonal *SARS-CoV* (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .

HY-P9802

Anti-Spike-RBD Single Domain mAb SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody	SARS-CoV	Infection
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .

HY-P99556

Tixagevimab AZD8895	SARS-CoV	Infection
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the *SARS-CoV-2* receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .

HY-P99103

Bebtelovimab LY-3853113; LY-CoV1404	SARS-CoV	Infection
Bebtelovimab a humanized IgG1-λ2 antibody targeting to *SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV*-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .

HY-P99604

Cilgavimab AZD-1061; CoV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-P99710

Lomtegovimab BI 767551; DZIF-10c	SARS-CoV	Infection
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .

HY-P99340

Sotrovimab VIR 7831	SARS-CoV	Infection
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

HY-P990052

Simaravibart

MAD-0004J08
SARS-CoV Infection

Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .

HY-P99947

Rimteravimab XVR011	SARS-CoV	Infection
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .

HY-P99889

Romlusevimab BRII-198	SARS-CoV	Infection
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .

HY-145641

Crexavibart BMS-986413; C-144-LS	SARS-CoV	Infection
Crexavibart (BMS-986413; C-144-LS) is an IgG1_λ2 antibody that targets the *SARS-CoV2* spike (S) glycoprotein receptor-binding domain .

HY-145644

Ogalvibart C-135-LS; BMS-986414	SARS-CoV	Infection
Ogalvibart (C-135-LS) is a *human anti-SARS-CoV-2 monoclonal antibody* (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of *SARS-CoV-2*. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-P99346

Regdanvimab CT-P59	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of *SARS-CoV-2* spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .

HY-P99467

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of *SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC₅₀* value of 14.9 ng/mL and a K_d of 0.21 nM .

HY-P99376

Narsoplimab OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)	SARS-CoV	Infection
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .

HY-145642

Masavibart ZRC3308-A7	SARS-CoV	Infection
Masavibart (ZRC3308-A7) is an *anti-SARS-CoV-2 monoclonal antibody* (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the *SARS-CoV-2* spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-145643

Nepuvibart ZRC3308-B10	SARS-CoV	Infection
Nepuvibart (ZRC3308-B10) is an *anti-SARS-CoV-2 monoclonal antibody* (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the *SARS-CoV-2* spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-P99012

Clazakizumab	Interleukin Related SARS-CoV	Infection Inflammation/Immunology
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .

HY-P99342

Imdevimab REGN10987	SARS-CoV	Infection
Imdevimab (REGN10987) is a human monoclonal antibody to target *SARS-CoV-2* virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .

HY-P99341

Casirivimab REGN10933	SARS-CoV	Infection
Casirivimab (REGN10933) is a human monoclonal antibody to target *SARS-CoV-2* virus, which causes COVID-19. Casirivimab lacks efficacy against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), it reduces viral load and improves diseases .

HY-P99347

Etesevimab

CB 6; JS016
SARS-CoV Angiotensin-converting Enzyme (ACE) Infection

Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .
HY-P99104

Plutavimab

CoVI-AMG; STI-2020
SARS-CoV Infection

Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17470

Mizoribine 4 Publications Verification NSC 289637; HE 69	Alkaloids Structural Classification Microorganisms Classification of Application Fields Source classification Inflammation/Immunology Disease Research Fields	HCV SARS-CoV Antibiotic Parasite
Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant . Mizoribine, an IMPDH inhibitor, inhibits replication of *SARS-CoV* with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively .

HY-N2949

Bonducellpin D	Other Terpenoids Infection Caesalpinia minax Hance Classification of Application Fields Leguminosae Terpenoids Source classification Plants Disease Research Fields	SARS-CoV
Bonducellpin D is a furanoditerpenoid lactone isolated from Caesalpinia minax. Bonducellpin D exhibits broad-spectrum inhibition potential against SARS-CoV M ^pro and MERS-CoV M ^pro, with an K_i of 467.11 and 284.86 nM, respectively. Bonducellpin D also exhibits moderate anti-cancer activity in vitro .

HY-N144101

SARS-CoV MPro-IN-2	Infection Quinones Classification of Application Fields Source classification Plants Lithospermum canescens Lehm. Naphthalene Quinones Disease Research Fields Boraginaceae	SARS-CoV
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M ^pro with an IC₅₀ value of 72.07 nM. The main protease (M ^pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .

HY-N11896A

10-Hydroxyaloin A	Structural Classification Natural Products Liliaceae Source classification Aloe vera (L.) Burm. f. Plants	SARS-CoV
10-10-Hydroxyaloin A is potent *SARS-CoV-2* inhibitor. 10-Hydroxyaloin A exhibits significant efficacy to bind SARS-Cov-2 M_pro active site .

HY-126416

Methyl tanshinonate	Structural Classification Natural Products Labiatae Source classification Samanea saman (Jacq.) Merr. Plants	SARS-CoV
Methyl tanshinonate is a tanshinone, that can be isolated from Salvia miltiorrhiza (S. miltiorrhiza) Bunge (Lamiaceae). Methyl tanshinonate is a potent inhibitor of M ^pro enzyme in *SARS-CoV* (IC₅₀ = 21.1 µM). Methyl tanshinonate can be used for diabetes and SARS-CoV research .

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Infection Structural Classification Microorganisms Source classification Polyphenols Disease Research Fields	Bacterial Antibiotic
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Structural Classification Source classification Phenols Polyphenols Endogenous metabolite	Antibiotic HIV SARS-CoV
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-N10604

Dihydromaniwamycin E	Natural Products Microorganisms	Influenza Virus SARS-CoV
Dihydromaniwamycin E is a heat-shock metabolite with antiviral activity against influenza and *SARS-CoV-2* viruses .

HY-126085

(±)-Alliin 2 Publications Verification (±)-L-Alliin	Infection Structural Classification Liliaceae Classification of Application Fields Ketones, Aldehydes, Acids Source classification Plants Disease Research Fields A．Sativam L. var．Viviparum Regel	SARS-CoV
(±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (M_pro) .

HY-N8599

Cichoriin	Infection Structural Classification Monophenols other families Classification of Application Fields Source classification Coumarins Phenols Phenylpropanoids Plants Disease Research Fields	SARS-CoV
Cichoriin is an active compounds against *SARS-CoV-2*, and may be a potential candidate in researching severe COVID-19 .

HY-N12384

(25S)-Antcin B	Triterpenes Structural Classification Microorganisms Terpenoids Source classification	SARS-CoV
Antcin-B is a potent inhibitor of 3CLPro with high affinity. Antcin-B can be used in study *SARS-CoV-2* .

HY-N10605

Maniwamycin E	Natural Products Microorganisms	SARS-CoV Influenza Virus
Maniwamycin E is a maniwamycin derivative isolated from the culture extract of thermotolerant Streptomyces sp. JA74. Maniwamycin E shows antiviral activity against SARS-CoV-2 and influenza (H1N1) virus .

HY-N8306

Isojacareubin	Structural Classification Flavonoids Flavones Source classification Guttiferae Plants Hypericum japonicum Thunb. ex Murray	Bacterial PKC Apoptosis SARS-CoV
Isojacareubin can be isolated from Hypericum japonicum. Isojacareubin covalently inhibits SARS-CoV-2 3CLpro. Isojacareubin also has anti-helicobacter activity. Isojacareubin inhibits PKC, and suppresses hepatocellular carcinoma metastasis and induces apoptosis .

HY-18234A

Leupeptin hemisulfate 25+ Cited Publications	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Inflammation/Immunology Disease Research Fields	Cathepsin Ser/Thr Protease Virus Protease
Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits M ^pro (the main protease of *SARS-CoV-2*) and also has anti-inflammatory activity .

HY-N10109A

Gallinamide A TFA	Structural Classification Natural Products Microorganisms Source classification	SARS-CoV Parasite Cathepsin
Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC₅₀: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC₅₀: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC₅₀: 50 nM) .

HY-13433

Thapsigargin Maximum Cited Publications 51 Publications Verification	Infection Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Umbelliferae Disease Research Fields Cancer Thapsia garganica L.	Calcium Channel SARS-CoV Apoptosis
Thapsigargin, an endoplasmic reticulum (ER) stress inducer, is an inhibitor of microsomal Ca ²⁺-ATPase. Thapsigargin efficiently inhibits coronavirus (HCoV-229E, MERS-CoV, SARS-CoV-2) replication in different cell types .

HY-N3445

Jaceidin triacetate	Sclerocarya birrea (A.Rich.) Hochst. Structural Classification Flavonoids Flavones Source classification Plants Anacardiaceae	SARS-CoV
Jaceidin triacetate(compound 54) is a natural compound isolated formmarulabark.Jaceidin triacetatecan inhibitSARS-CoV-2 Mpro, with theIC₅₀of 11.9μM.Jaceidin triacetateinhibits the replication of Sars-Cov-2 Viral in Vero-E6 cells .

HY-N1996

Chebulagic acid 2 Publications Verification	Classification of Application Fields Combretaceae Source classification Phenols Polyphenols Terminalia chebula Retz. Plants Inflammation/Immunology Disease Research Fields	COX Lipoxygenase SARS-CoV Influenza Virus
Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a M2 serine to asparagine 31 mutation (S31N) inhibitor and influenza antiviral. Chebulagic acid also against *SARS-CoV-2* viral replication with an EC₅₀ of 9.76 μM.

HY-N2355

Solasurine	Alkaloids Piperidine Alkaloids Structural Classification Classification of Application Fields Solanum surattense Burm. F. Source classification Other Diseases Plants Solanaceae Disease Research Fields	SARS-CoV
Solasurine is a steroidal alkaloid that can be isolated from Solanum surrattence. Solasurine can interact with the C3-like protease (SARS-CoV-2 main protease) amino acids Phe8, Pro9, Ile152, Tyr154, Pro293, Phe294, Val297, and Arg298 .

HY-16050

Plitidepsin 2 Publications Verification Aplidine; PM90001	Structural Classification Microorganisms Marine natural products Source classification Other marine organisms	DNA/RNA Synthesis SARS-CoV
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against *SARS-CoV-2* with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-N7073

Silymarin 4 Publications Verification	Infection Structural Classification Natural Products Glycine soya Neurological Disease Classification of Application Fields Source classification Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Inflammation/Immunology Disease Research Fields	SARS-CoV
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (M ^pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research .

HY-107577

Gedunin	Infection Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields	HSP
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent Hsp90 inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-137984

Cnicin	Structural Classification Natural Products Source classification Centaurea benedicta (L.) L. Plants Compositae	SARS-CoV
Cnicin is a sesquiterpene lactone. Cnicin has antiproliferative effects, and induces cell death in primary myeloma cells. Cnicin also has anti-SARS-CoV-2 activity. Cnicin inhibits viral replication of SARS CoV-2 with an IC₅₀ of 1.18 μg/mL .

HY-126419

Kobophenol A	Infection Classification of Application Fields Source classification Cyperaceae Phenols Polyphenols Plants Disease Research Fields Carex kobomugi Ohwi	SARS-CoV PKC
Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC₅₀ of 1.81 μM and inhibits *SARS-CoV-2* viral infection in cells with an EC₅₀ of 71.6 μM. Kobophenol A inhibits the activity of partially purified rat brain protein kinase C (PKC) with an IC₅₀ of 52 µM .

HY-N10118

NK007	Infection Alkaloids Structural Classification Cynanchum mongolicum (Maximowicz) Hemsley Pyrrole Alkaloids Classification of Application Fields Source classification Asclepiadaceae Plants Isoquinoline Alkaloids Disease Research Fields	SARS-CoV
NK007 is a novel anti-SARS-CoV-2 agent with an EC₅₀ value of 30 nM.

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-N0063

Punicalagin 5 Publications Verification	Infection Structural Classification Punica granatum L. Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Punicaceae Plants Disease Research Fields	SARS-CoV HBV
Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CL ^pro inhibitor and inhibits *SARS-CoV-2* replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 .

HY-110066

(Z)-Guggulsterone 2 Publications Verification	Classification of Application Fields Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Disease Research Fields Steroids Cancer	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and *SARS-CoV-2* infection .

HY-B0157A

Ketotifen fumarate 1 Publications Verification HC 20511 fumarate	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Histamine Receptor Endogenous Metabolite SARS-CoV Influenza Virus
Ketotifen (HC 20-511) fumarate is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen fumarate can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen fumarate also has antiviral activity against *SARS-CoV-2* and Influenza virus. Ketotifen fumarate can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention .

HY-N10661

Ipomoeassin F Ipom-F	Structural Classification Natural Products Ipomoea squamosa Choisy Plants Convolvulaceae	SARS-CoV
Ipomoeassin F is a potent and selective endoplasmic reticulum (ER) protein-translocation inhibitor by targeting the pore-forming subunit of the Sec61 complex (Sec61α) at the ER membrane. Ipomoeassin F selectively inhibits the ER membrane translocation of SARS-CoV-2 proteins. Ipomoeassin F block the ER translocation of secretory proteins and type I transmembrane proteins (TMPs), but not type III TMPs .

HY-N12110

SMU-CX1	Apocynaceae Structural Classification Alkaloids Other Alkaloids Source classification Plants	Toll-like Receptor (TLR) SARS-CoV
SMU-CX1 is a specific TLR3 inhibitor (IC₅₀: 0.11 μM) with IC₅₀ ranging from 0.14-0.33 μM against multiple influenza A virus subtypes. SMU-CX1 inhibits the viral PB2 and NP proteins with an IC₅₀ of 0.43 μM for SARS-CoV-2 activity. SMU-CX1 also inhibits inflammatory factors in host cells, including IFN-β, IP-10, and CCL-5 .

HY-W012531

2-Hydroxycinnamic acid	Infection Structural Classification Monophenols Cinnamomum cassia (L.) D. Don Classification of Application Fields Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Lauraceae Disease Research Fields	HIV SARS-CoV Endogenous Metabolite
2-Hydroxycinnamic acid is isolated from the methanol extract of Cinnamomum cassia. 2-Hydroxycinnamic acid shows inhibitory effects on infection of *HIV/SARS-CoV* S pseudovirus with an IC₅₀** of 0.3 mM

HY-W002198

2-Hydroxyacetophenone Phenacyl alcohol	Infection Apocynaceae Carissa edulis Structural Classification Natural Products Classification of Application Fields Plants Disease Research Fields	HIV SARS-CoV
2-Hydroxyacetophenone is a principal root volatile of the Carissa edulis . 2-Hydroxyacetophenone shows inhibitory effects on infection of *HIV/SARS-CoV* S pseudovirus with an IC₅₀** of 1.8 mM .

HY-N11902

1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one	Structural Classification Source classification Phenols Polyphenols Plants Curcuma longa Zingiberaceae	SARS-CoV
1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one is a potent nucleocapsid (N) protein inhibitor can be isolated from Curcuma kwangsiensis. 1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one exhibits excellent antiviral activity against HCoV-OC43 and SARS-CoV-2,with EC₅₀ values of 0.16 μM and 0.17 μM, respectively .

HY-N1913

Danshensu 1 Publications Verification Dan shen suan A; Salvianic acid A	Structural Classification Classification of Application Fields Simple Phenylpropanols Labiatae Samanea saman (Jacq.) Merr. Source classification Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Cancer	Keap1-Nrf2 NF-κB Reactive Oxygen Species SARS-CoV Apoptosis
Danshensu (Dan shen suan A), an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu displays a potent antiviral activity against *SARS-CoV-2* with EC₅₀ of 0.97 μM. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research .

HY-N1913A

Danshensu sodium Dan shen suan A sodium; Salvianic acid A sodium	Structural Classification Simple Phenylpropanols Labiatae Source classification Samanea saman (Jacq.) Merr. Phenols Polyphenols Phenylpropanoids Plants	Keap1-Nrf2 NF-κB Reactive Oxygen Species SARS-CoV Apoptosis
Danshensu (Dan shen suan A) sodium, an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu sodium reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu sodium displays a potent antiviral activity against *SARS-CoV-2* with EC₅₀ of 0.97 μM. Danshensu sodium has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research .

HY-15310

Ivermectin 15+ Cited Publications MK-933	Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Antiviral Anti-parasitic Disease Research Disease Research Fields Cancer	Flavivirus Dengue virus Parasite HIV Mitophagy HSV SARS-CoV Antibiotic Autophagy Bacterial
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against *SARS-CoV-2/COVID-19* .

HY-N9351

Cleistanthin B Diphyllin O-glucoside	Cardiovascular Disease Infection other families Classification of Application Fields Source classification Lignans Metabolic Disease Phenylpropanoids Plants Disease Research Fields	SARS-CoV
Cleistanthin B (Diphyllin O-glucoside) is an orally active arylnaphthalene lignan lactone glycoside. Cleistanthin B exhibits anti-SARS-CoV-2 effects in Vero cells, with EC₅₀ of 6.51 µM. Cleistanthin B also exhibits antitumor, diuretic and antihypertensive effects in vivo .

HY-B1028

Pantethine 1 Publications Verification D-Pantethine; LBF disulfide	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite SARS-CoV
Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-14393

Emodin 15+ Cited Publications Frangula emodin	Structural Classification Classification of Application Fields Polygonaceae Source classification Plants Endogenous metabolite Quinones Human Gut Microbiota Metabolites Microorganisms Rheum palmatum L. Anthraquinones Phenols Polyphenols Disease Research Fields Cancer	SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-14393R

Emodin (Standard) Frangula emodin (Standard)	Quinones Structural Classification Classification of Application Fields Rheum palmatum L. Polygonaceae Source classification Phenols Plants Disease Research Fields Cancer	SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Standard) is the analytical standard of Emodin. This product is intended for research and analytical applications. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-N6972

Cepharanthine 3 Publications Verification	Infection Structural Classification Alkaloids Stephania cepharantha Hayata Classification of Application Fields Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Menispermaceae Stephania japonica (Thunb.) Miers	SARS-CoV Cytochrome P450 Apoptosis Parasite
Cepharanthine is a natural product that can be isolated from the plant Stephania cephalantha Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC₉₀) values of 1.90 and 4.46 µM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

Cat. No.	Product Name	Chemical Structure

HY-104077S

Remdesivir-d5 2 Publications Verification
Remdesivir-d₅ is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro[1][2].

HY-135853S

Molnupiravir-d7

Molnupiravir-d₇ is the deuterium labeled Molnupiravir. Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].

HY-104077S1

Remdesivir-d4
Remdesivir-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-104077S2

Remdesivir impurity 9-d4
Remdesivir impurity 9-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-10241S

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-17007S

Saquinavir-d9
Saquinavir-d₉ is the deuterium labeled Saquinavir. Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.36 μM[1][2].

HY-90001S

Ritonavir-d6
Ritonavir-d₆ is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM[1][2].

HY-90001S1

Ritonavir-13C,d3
Ritonavir- ¹³C,d₃ is the ¹³C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.

HY-17430S1

Amprenavir-d4-1
Amprenavir-d₄-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-17430S

Amprenavir-d4
Amprenavir-d₄ is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM[1][2].

HY-B0462AS

Azelastine-13C,d3
Azelastine- ¹³C,d₃ is deuterium labeled Azelastine. Azelastine, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2[1][2][3][4].

HY-145119S

Mindeudesivir
GS-621763-d₁ is the deuterium labeled GS-621763 (HY-145119) . GS-621763, an orally bioavailable proagent of GS-441524, shows antiviral activity against *SARS-CoV-2* pathogenesis in mice .

HY-B0190S1

Nafamostat formate salt-13C6
Nafamostat formate salt- ¹³C₆ is the ¹³C labeled Nafamostat[1]. Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2[2][3][4][5].

HY-W031727S

Hydroxychloroquine-d4-1 sulfate
Hydroxychloroquine-d₄-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].

HY-W031727S1

Hydroxychloroquine-d5
Hydroxychloroquine-d₅ is the deuterium labeled Hydroxychloroquine[1]. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].

HY-B1370S

Hydroxychloroquine-d4 sulfate
Hydroxychloroquine-d₄ (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].

HY-15602S

Ledipasvir-d6
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].

HY-B0372AS

Bromhexine-d3 hydrochloride

Bromhexine-d₃ (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions[1][2][3][4].

HY-100442S

Paquinimod-d5
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-P5168S

GPSVFPLAPSSK-13C6
GPSVFPLAPSSK- ¹³C₆ is the ¹³C labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .

HY-90001S3

rel-Ritonavir-d6
rel-Ritonavir-d₆ (rel-ABT 538-d₆; rel-RTV-d₆) is the deuterium labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-100442S1

Paquinimod-d5-1
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-10237S

Boceprevir-d9
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].

HY-17589AS

Chloroquine-d5 1 Publications Verification
Chloroquine-d₅ is deuterium labeled Chloroquine. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-17589S1

Chloroquine-d4 phosphate

Chloroquine-d₄ (phosphate) is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-17589S

Chloroquine-d5 diphosphate

Chloroquine-d₅ (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-14904AS

Umifenovir-d6 hydrochloride

Umifenovir-d₆ (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells[1][2]. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity[3].

HY-B0462S

Azelastine-13C,d3 hydrochloride
Azelastine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Azelastine hydrochloride. Azelastine- ¹³C,d₃ (hydrochloride), an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine- ¹³C,d₃ (hydrochloride) can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2[1][2][3][4].

HY-15463S2

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-145119AS

Mindeudesivir hydrobromide
Mindeudesivir (JT001; VV116; GS-621763-d₁) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against *SARS-CoV-2* and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .

HY-17367S3

Atazanavir-d5
Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9
Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].

HY-17367S4

Atazanavir-d6
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-14588S1

Lopinavir-d8
Lopinavir-d₈ (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM[3].

HY-119980S

Fluphenazine-d8

Fluphenazine-d₈ is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .

HY-14588S

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈)is the deuterium labeledLopinavir(HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-113478S

Ursodeoxycholic acid-2,2,4,4-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].

HY-B1028S

Pantethine-15N2

Pantethine- ¹⁵N₂ is the ¹⁵N₂ labeled Pantethine. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-14393S

Emodin-d4

Emodin-d₄ is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks